Cargando…
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
The antibody trastuzumab (Herceptin) has substantially improved overall survival for patients with aggressive HER2-positive breast cancer. However, about 70% of all treated patients will experience relapse or disease progression. This may be related to an insufficient targeting of the CD44(high)CD24...
Autores principales: | Diessner, J, Bruttel, V, Stein, R G, Horn, E, Häusler, S F M, Dietl, J, Hönig, A, Wischhusen, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3973200/ https://www.ncbi.nlm.nih.gov/pubmed/24675467 http://dx.doi.org/10.1038/cddis.2014.115 |
Ejemplares similares
-
Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019) -
Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)
por: Corbin, Kimberly S., et al.
Publicado: (2020) -
Activity of trastuzumab emtansine (T-DM1) in 3D cell culture
por: Boyer, Jean Zheng, et al.
Publicado: (2021) -
Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021) -
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
por: Fujihara, Miwa, et al.
Publicado: (2021)